Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing selective fatty acid synthase (FASN) inhibitors to treat diseases caused by the overproduction of palmitate. FASN is a key enzyme involved in the synthesis of saturated fatty acids in the liver and other organs, and it is the only enzyme capable of converting metabolic sugars into palmitate. Excessive production of palmitate is a significant driver of cellular metabolic dysfunction, which can lead to the onset or progression of various diseases. The company believes that FASN inhibitors hold therapeutic potential across multiple disease areas, including liver diseases, cancer, and more.